Effect of SRM-Ⅳ Vestibular Function Diagnosis System Combined with Betasteine in Treating Benign Paroxysmal Positional Vertigo and Its Effect on Serological Index Level
Objective To investigate the effect of SRM-Ⅳ vestibular function treatment system combined with betahistine on benign paroxysmal positional vertigo(BPPV)and its effect on serological index level.Methods 105 BPPV patients admitted to the hospital from November 2021 to November 2023 were selected as the study objects.They were divided into a control group(n=53)and an observation group(n=52)according to random table method.The control group was treated with SRM-Ⅳ vestibular functional diagnosis and treatment system combined with conventional drugs,and the observation group was treated with SRM-Ⅳ vestibular functional diagnosis and treatment system combined with betahistine.The Vertigo Symptom Scale-Shor Form(VSS-SF),Berg Balance Scale(BBS)scores,β-Amyloid Precursor Protein(β-APP),microtubule associated protein(Tau),calcitonin gene-related peptide(CGRP)levels,Dizziness Handicap Inventory(DHI)scores and the occurrence of adverse reactions were observed in two groups.Results Before treatment,there were no significant differences in VSS-SF and BBS scores between the two groups(P＞0.05);after treatment,the VSS-SF score of the observation group was lower than that of the control group,and the BBS score was higher than that of the control group,with statistical significance between the two groups(P＜0.05).Before treatment,there were no significant differences in β-APP,Tau and CGRP levels between the two groups(P＞0.05);after treatment,the levels of β-APP,Tau and CGRP in the observation group were lower than those in the control group,and the differences between groups were statistically significant(P＜0.05).Before treatment,there was no significant difference in DHI scores between the two groups(P＞0.05);after treatment,the DHI score of the observation group was lower than that of the control group,and the difference was statistically significant(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion The combination of betahistine and SRM-Ⅳ vestibular function diagnosis and treatment system in BPPV patients can effectively improve the vertigo symptoms,reduce the degree of brain damage,improve the quality of life,and the drug safety is good.
NETL
NSTL
万方数据
